4.7 Review

Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia

期刊

TRENDS IN PHARMACOLOGICAL SCIENCES
卷 32, 期 9, 页码 507-513

出版社

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2011.05.001

关键词

-

资金

  1. Johnson Johnson
  2. Lundbeck
  3. Pfizer
  4. GSK
  5. Puretech Ventures
  6. Merck
  7. Takeda
  8. Dainippon Sumitomo

向作者/读者索取更多资源

Substantial evidence suggests that psychosis in schizophrenia is associated with dysregulation of subcortical dopamine system function. Here we examine evidence that this dysregulation is secondary to hyperactivity within hippocampal subfields. Enhanced hippocampal activity has been reported in preclinical models and in schizophrenia patients. Moreover, this hippocampal hyperactivity is correlated with enhanced dopamine neuron activity and positive symptoms, respectively. Thus, restoration of hippocampal function could provide a more effective therapeutic approach than current therapeutics based on blockade of dopamine 02 receptors. Indeed, initial studies demonstrate that allosteric modulation of the alpha 5GABA(A) receptor can decrease aberrant dopamine signaling and associated behaviors in a verified rodent model of psychosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据